A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical ocular parameters in Iraqi patients following cataract surgery

A comparative study of the effects of topical... | F1000Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://f1000research.com/js/vendor/ckeditor/' window.reactTheme = 'research'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); (function(h,o,t,j,a,r){ h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)}; h._hjSettings={hjid:2318163,hjsv:6}; a=o.getElementsByTagName('head')[0]; r=o.createElement('script');r.async=1; r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv; a.appendChild(r); })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv='); search file_upload Submit your research search menu close search Browse Gateways & Collections How to Publish Submit your Research My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Open Data, Software and Code Guidelines (PSE) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Article Processing Charges Peer Review Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Newsroom Contact My Research Submissions Content and Tracking Alerts My Details Sign In file_upload Submit your research { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://f1000research.com/articles/14-114" }, "headline": "A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical...", "datePublished": "2025-01-20T16:03:07", "dateModified": "2025-01-20T16:03:07", "author": [ { "@type": "Person", "name": "Leqaa Basil Taha" }, { "@type": "Person", "name": "Mohammed Qasim Yahya Malallah A. Al-Atrakji" }, { "@type": "Person", "name": "zaid Rajab Hussein" } ], "publisher": { "@type": "Organization", "name": "F1000Research", "logo": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 480, "width": 60 } }, "image": { "@type": "ImageObject", "url": "https://f1000research.com/img/AMP/F1000Research_image.png", "height": 1200, "width": 150 }, "description": " Background Cataracts are an assortment of conditions causing the lens to become opaque and lose its typical transparency. Topical corticosteroids like loteprednol etabonate and dexamethasone are commonly administered to alleviate inflammation following cataract surgery. Aim of the study To compare the efficacy of loteprednol etabonate and dexamethasone in managing different clinical parameters following cataract removal, as well as their patient safety. Methods This trial was registered by local IRB at the College of Medicine/University of Baghdad on November 27, 2023, under document approval number UoB.Med.21. Patients undergoing cataract surgery were randomly assigned to two groups: group A received loteprednol etabonate 0.5% drop postoperatively for four weeks, while group B received dexamethasone 0.1% drop postoperatively for the same period. The levels of intraocular pressure (IOP), anterior chamber (AC) reaction, and scores for flare, conjunctival congestion, and pain were monitored at one and four weeks during follow-up visits. Results The visual outcomes were similar between the two groups, and both treatments were well tolerated with minor side effects. Both loteprednol etabonate and dexamethasone effectively reduced IOP, AC reaction, and grading for flare, conjunctival congestion, and pain in cataract patients. None of these clinical measures displayed any significant differences between the two drugs. Conclusion There is no significant difference between topical loteprednol etabonate 0.5% and topical dexamethasone 0.1% pertaining to clinical ocular parameters post-cataract surgery. The decision between these corticosteroids may depend on patient needs and preferences. " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://f1000research.com/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://f1000research.com/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://f1000research.com/articles/14-114", "name": "A comparative study of the effects of topical dexamethasone 0.1% and..." } } ] } Home Browse A comparative study of the effects of topical dexamethasone 0.1% and... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Taha LB, Al-Atrakji MQYMA and Hussein zR. A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical ocular parameters in Iraqi patients following cataract surgery [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :114 ( https://doi.org/10.12688/f1000research.158920.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Research Article A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical ocular parameters in Iraqi patients following cataract surgery [version 1; peer review: awaiting peer review] Leqaa Basil Taha https://orcid.org/0009-0009-1995-0990 1 , Mohammed Qasim Yahya Malallah A. Al-Atrakji https://orcid.org/0000-0001-5047-5854 2 , zaid Rajab Hussein https://orcid.org/0009-0005-5128-0844 3 Leqaa Basil Taha https://orcid.org/0009-0009-1995-0990 1 , Mohammed Qasim Yahya Malallah A. Al-Atrakji https://orcid.org/0000-0001-5047-5854 2 , zaid Rajab Hussein https://orcid.org/0009-0005-5128-0844 3 PUBLISHED 20 Jan 2025 Author details Author details 1 Msc candidate (Pharmacology), Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, +964, Iraq 2 PhD (Pharmacology), Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, Iraq 3 Republic of Iraq Ministry of Health, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq Leqaa Basil Taha Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software Mohammed Qasim Yahya Malallah A. Al-Atrakji Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization zaid Rajab Hussein Roles: Conceptualization, Investigation, Software, Supervision, Validation, Visualization OPEN PEER REVIEW REVIEWER STATUS AWAITING PEER REVIEW This article is included in the Eye Health gateway. Abstract Background Cataracts are an assortment of conditions causing the lens to become opaque and lose its typical transparency. Topical corticosteroids like loteprednol etabonate and dexamethasone are commonly administered to alleviate inflammation following cataract surgery. Aim of the study To compare the efficacy of loteprednol etabonate and dexamethasone in managing different clinical parameters following cataract removal, as well as their patient safety. Methods This trial was registered by local IRB at the College of Medicine/University of Baghdad on November 27, 2023, under document approval number UoB.Med.21. Patients undergoing cataract surgery were randomly assigned to two groups: group A received loteprednol etabonate 0.5% drop postoperatively for four weeks, while group B received dexamethasone 0.1% drop postoperatively for the same period. The levels of intraocular pressure (IOP), anterior chamber (AC) reaction, and scores for flare, conjunctival congestion, and pain were monitored at one and four weeks during follow-up visits. Results The visual outcomes were similar between the two groups, and both treatments were well tolerated with minor side effects. Both loteprednol etabonate and dexamethasone effectively reduced IOP, AC reaction, and grading for flare, conjunctival congestion, and pain in cataract patients. None of these clinical measures displayed any significant differences between the two drugs. Conclusion There is no significant difference between topical loteprednol etabonate 0.5% and topical dexamethasone 0.1% pertaining to clinical ocular parameters post-cataract surgery. The decision between these corticosteroids may depend on patient needs and preferences. READ ALL READ LESS Keywords Anterior Chamber; Cataract; Dexamethasone; Intraocular pressure; Loteprednol etabonate; Conjunctival congestion Corresponding Author(s) Leqaa Basil Taha ( [email protected] ) Close Corresponding author: Leqaa Basil Taha Competing interests: No competing interests were disclosed. Grant information: The author(s) declared that no grants were involved in supporting this work. Copyright: © 2025 Taha LB et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Taha LB, Al-Atrakji MQYMA and Hussein zR. A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical ocular parameters in Iraqi patients following cataract surgery [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :114 ( https://doi.org/10.12688/f1000research.158920.1 ) First published: 20 Jan 2025, 14 :114 ( https://doi.org/10.12688/f1000research.158920.1 ) Latest published: 20 Jan 2025, 14 :114 ( https://doi.org/10.12688/f1000research.158920.1 ) Introduction One of the most frequent operations performed in ophthalmology clinics is the removal of cataracts and the implantation of posterior chamber intraocular lenses. The word cataract refers to a heterogeneous group of conditions characterized collectively by an opacification in the substance or capsule of the crystalline lens. 1 Cataract remains the leading cause of global blindness, accounting for approximately 21.2% to 91.1% of blindness; this wide range is attributed to the demographic characteristics of the studied samples and, most importantly, to the level of socioeconomic development in their countries of origin. 2 However, cataract is categorized into two types: congenital and acquired; the latter is frequently age-related, but can also occur as a result of trauma, chemical exposure, radiation, drugs, systemic diseases such as diabetes, and others. 3 , 4 Diabetic Mellitus (DM) is the primary cause of visual impairment among individuals between 20 and 65. While total blindness in diabetes is rare, affecting less than 2% of individuals, the fear of losing vision is significant. This is validated by diabetics who experience changes in their vision and eye examination is recommended to address any potential issues. 5 , 6 Although the prevalence of diabetes has been increasing at a faster rate in middle- and low-income countries, the association between diabetes and cataracts is still ongoing. 6 One theory is the sorbitol accumulation theory, which states that an increase in blood glucose raises the glucose content of the aqueous humour beyond the lens tissue’s ability to metabolize it, which increases sorbitol production through alternative pathways and causes areas of increased density 7 – 9 Excess glucose metabolism may increase oxygen-free radical production, according to another theory. 10 – 14 Phacoemulsification cataract surgery (PCS) was initially introduced over 50 years ago, initially devised visual by Charles Kelman in 1967. His objective was to eliminate the cataract with a smaller incision, reduce pain, and a shortened recovery period, presently, it is the preferable method, and satisfactory outcomes are typically associated with this uneventful surgery. 15 , 16 Opacification of the lens in cataracts is a function of increased light attenuation due to the accumulation of crosslinked proteins and pigments. The exact cause and portion of the lens affected by this accumulation differ according to the type of cataract; in age-related cataracts, for example, the cause is cumulative oxidative stress over time, which denatures proteins and reduces their solubility. 17 , 18 The intraocular pressure might be changed postoperatively, for example, low intraocular pressure can present postoperatively either due to aqueous loss during the operation or due to continuous leak from the non-sutured incision during the postoperative period or inflammation. This reduction in intraocular pressure is documented following uncomplicated phacoemulsification. 19 – 21 On the other hand, a transient increase in intraocular pressure can occur following 18% of cataract extraction surgeries due to reduced drainage of aqueous humor by the trabecular meshwork. 17 , 22 Despite recent developments in surgical techniques, complications are still possible while undergoing regional anesthesia. 23 , 24 To reduce postoperative inflammation and its consequences, including corneal edema and cystoid macular edema, topical antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroid drops might be used for the first one to four weeks after the operation. In addition, it is usually recommended to use eye patches on day one postoperatively and protective shields during the night for the first few days after surgery. 17 Follow-up is indicated at one day, one week, four weeks, and three months after the operation. However, there is controversy over the choice of anti-inflammatory medication and whether NSAIDs or corticosteroids give a superior prophylactic alternative for postoperative inflammation. 25 Different countries and regions can opt for both based on specific regulations, but no agreement has been achieved, and there are no gold standard treatment choices. This discussion also includes which drugs to use within the same class of anti-inflammatory treatment, such as how two corticosteroids, Loteprednol Etabonate and topical dexamethasone, compare in terms of efficacy and safety in the treatment of postoperative inflammation. 26 , 27 Corticosteroids constitute the first-line therapy for a variety of ocular disorders impacting the ocular surface, anterior and posterior portions of the eye thanks to their anti-inflammatory, anti-mitotic, vasoconstrictive, immunosuppressive, and anti-edematous characteristics. 28 – 31 The pharmacological action of glucocorticoids is achieved by the cytosolic glucocorticoid receptors which when activated induces structural modifications and relocates to the nucleus. 32 – 36 The excited glucocorticoid receptor promotes or represses transcriptional elements, resulting in both therapeutic and detrimental consequences. These activities prevent the synthesis of arachidonic acids and their related eicosanoid metabolites. 37 – 41 This has prompted an effect on the blood-tissue barriers, reducing fibroblast replication, collagen and scar development, ocular swelling, fibrin accumulation, vascular leakages, inflammatory cells escaping into the retina, and vascular endothelial growth factor (VEGF) levels. 42 – 46 To reduce postoperative inflammation and its consequences, including corneal edema and cystoid macular edema, corticosteroid drops might be used for the first few weeks after the operation, however, corticosteroids might affect intraocular pressure Steroid-induced IOP elevation has been reported to occur in 18–36 % of patients, termed steroid responders, with risk factors including a history of glaucoma, a familial predisposition toward glaucoma, or high myopia. 47 , 48 Older corticosteroids, such as prednisolone and dexamethasone, are associated with a greater impact on IOP compared to newer corticosteroids. 49 Dexamethasone is a glucocorticoid drug with a potent anti-inflammatory but virtually no mineralocorticoid effects on the kidney. It is the drug of choice in the prevention of respiratory distress syndrome (RDS) of premature infants and to investigations for Cushing syndrome. 39 , 50 Usage of dexamethasone is also indicated in situations where fluid retention can be a problematic side effect such as in the treatment of cerebral edema due to tumors and, in its topical forms, it can be used for inflammatory skin conditions and different types of ophthalmologic conditions including the postoperative prevention and treatment of complications following cataracts surgery. 51 , 52 Loteprednol Etabonate, unlike dexamethasone, is a corticosteroid designed specifically for inflammatory eye conditions and is administered as an eye drop for allergic conjunctivitis, uveitis, and episcleritis and the treatment or prevention of inflammation following eye surgery, including lens removal and replacement in cataracts. 53 Loteprednol etabonate is a corticosteroid produced by retro-metabolic design; an inactive and nontoxic metabolite of a reference compound is utilized as a starting point for conversion to a therapeutically active, metabolically labile compound. Structurally, loteprednol etabonate differs from prednisolone in that the ketone at the carbon-20 (C-20) position is replaced with a chloromethyl ester, and the 17α-hydroxyl group is replaced with a carbonate moiety and after exerting its effects, loteprednol etabonate is rapidly metabolized, thereby limiting any potential adverse effects associated with its use. 53 Aim of study This study investigates and compares the effect of topical loteprednol etabonate 0.5% and dexamethasone 0.1% on clinical ocular measures in post-cataract surgery. Methods This prospective examine turned into performed at the Jena Ophthalmic Center in Iraq over a duration from December 1, 2023, to August 28, 2024. As Iraq does not have its own number one registries, the examine was reviewed and accepted through the Institutional Review Board (IRB) of the College of Medicine, University of Baghdad. Approval turned into granted on November 27, 2023, beneath report authorization range UoB.Med.21. Participants have been furnished with a concise clarification of the have a look act’s objectives and methodologies before enrolling in the research. The study complied with the tenets of the Declaration of Helsinki, and all participants provided written informed consent before recruitment. The study enrolled adult patients diagnosed with cataracts, 18 years old or older, who prepared for and underwent cataract extraction surgery by phacoemulsification. The operations were done at Jena Ophthalmic Center in Baghdad, Iraq. Patients who had uveitis or a history of uveitis or glaucoma, used antiglaucoma medications, had complications during surgery, or didn’t comply with follow-up or medication were excluded from the study. The patients were examined preoperatively within one week of the surgery with complete history and examination and then the surgery was done by the same surgeon with preoperative pupillary dilatation by tropicamide 0.1% drop then phacoemulsification under local anesthesia using a 2.4mm limbal incision then filling the AC with sodium hyaluronate 1.4% (Aurogel) (is a cohesive viscoelastic formulation used for filling anterior chamber and better adhesiveness on the corneal endothelium during phacoemulsification pH 7.0 to 7.8/Available in a 1ml syringe/Catalogue number 803878032506/Aurolab-India) and anterior capsulorhexis was done then hydro dissection and application of methylcellulose HPMC2% (Aurovisc) to AC for corneal endothelial protection followed by phacoemulsification and cortical material removal and later the implantation of the intra-ocular lens (® is a monofocal foldable, single-piece posterior chamber acrylic lens with an Intraocular Lens 15.5D, Length 13.0 mm, Optic 6.0 mm/Fort Worth and Cork, Ireland) and lastly removal of methylcellulose and stromal hydration of the wound and padding.and lastly removal of methylcellulose and stromal hydration of the wound and padding. All the patients removed the pad 6 hours after the surgery and began the topical treatment and the Patients undergoing cataract surgery were randomly assigned to two groups using a computer-generated randomization table. Group 1: Patients received topical treatment with moxifloxacin (AROX Jamjom) drops and loteprednol drops 0.5% (Ajanta) four times daily. Group 2: Patients received topical treatment with moxifloxacin (AROX Jamjom) drop and dexamethasone 0.1% suspension drop (Edol) four times per day. In one week, all the patients were examined by the same physician and recorded IOP, AC reaction, AC flare, conjunctival congestion, and pain according to the questionnaire for both groups and then repeated the examination in four weeks and recording the same parameters. Assessment of study parameters All participants were assessed preoperatively, one week, and four weeks postoperatively using a pre-printed personal interview formula to collect the data for the following parameters: Intraocular pressure: Intraocular pressure is diagnosed with an air puff tonometer. AC and flare grading: AC reaction and flare were graded with a slit lamp using 1mm height and 1mm width high illumination and magnification light and scored according to Table 1 . 54 Table 1. Standraized grading scales for Uveitis. Standardized grading scales for Uveitis Sun grading scheme for anterior chamber cells Grade Cells in field 0 <1 +0.5 1-5 +1 6-15 +2 16-25 +3 26-50 +4 +50 Sun grading scheme for anterior chamber flare Grade Description 0 None +1 Faint +2 Moderate (iris/lens details clear) +3 Marked (iris/lens details hazy) +4 Intense (fibrin/plastic aqueous) Grading of conjunctival congestion was graded according to hyperemia at the limbus, 55 as in Table 2 . Table 2. Hyperemia at the limbus. Grade Intensity Extent of perilimbal conjunctival erythema 0 None All clear 0.5 Trace 1-90 Arc of Limbus 1 Mild 91-180 Arc of Limbus 1.5 Moderate 181-270 Arc of limbus 2 Severe 271-360 Arc of limbus Pain scoring: This was done through a questionnaire and recording accordingly, as in Table 3 . Table 3. Pain scoring. No pain 0 Mild pain (intermittent) 1 Moderate (more constant) 2 Sever (constant and need analgesia) 3 Statistical analysis For data entry analysis, Microsoft 360 and the Statistical Package for the Social Sciences (SPSS, Version 29) were utilized. Descriptive analysis was primarily concerned with frequencies and percentages. Continuous variables were represented as mean and (standard deviation). When the data were normally distributed, parametric tests were applied; otherwise, nonparametric tests were utilized. A P-value of 0.05 was employed to ascertain the level of significance, utilizing t-tests for parametric data and Mann-Whitney U tests for nonparametric comparisons. Results Sixty-six eyes of 66 patients were enrolled in the study with 33 participants with a mean age of 65±6.3 years assigned to group A and another 33 participants with a mean age of 64±12.7 assigned to group B with no clinically significant differences (P-value was 0.81), group A was dominated by males (60.6%) while group B was dominated by females (51.5%) but with no statistically significant distinction between the genders in distribution as shown in Table 4 . Based on the t-test and Mann-Whitney Test (p-value > 0.05), no statistically significant differences were observed between groups A and B regarding intraocular pressure preoperatively, one week post-operatively, and four weeks post-operatively as shown in Table 5 . Table 4. Patient demographic clinical features. Variables Group one Group two P- value Age 65±6.3 64±12.7 0.81 Gender Male 20 (60.6%) 16 (48.5%) 0.75 Female 13 (39.4%) 17 (51.5%) Table 5. Changes in intraocular pressure. Intraocular pressure Study Groups IOP Mean mmHg±St.D P-Value Preoperative Group A 16.45±3.00 0.522 Group B 16.42±2.76 0.481 1-week postoperatively Group A 15.82±3.00 0.523 Group B 15.61±2.81 0.490 4-weeks postoperatively Group A 15.58±2.11 0.379 Group B 16.55±4.45 0.775 There was no increase of IOP of ≥ 5 mmHg in either Group A or Group B after one week of treatment, while an increase of IOP of ≥5 mmHg occurred in only 3 patients (3/33 patients representing about 9.1%) treated with dexamethasone (Group B) after 4 weeks of treatment and none in group A. The Pearson chi-square test revealed no statistically significant difference between group A and group B regarding the AC grading one week post-operatively (p-value=0.607). With a p-value of 0.043, a statistically significant difference in the AC grading was observed between groups A and B after four weeks of operation ( Table 6 ). Table 6. the AC grading one week and four weeks post-operatively. Study Groups P-value Group A Group B No. of cells No. % No. % AC Grading after 1-week post-op < 1 5 15.2% 8 24.2% 0.607 1-5 13 39.4% 13 39.4% 6-15 11 33.3% 11 33.3% 16-25 3 9.1% 1 3.0% 26-50 1 3.0% 0 0.0% + 50 0 0.0% 0 0.0% AC Grading after 4 weeks post-op < 1 16 50.0% 23 69.7% 0.043 1-5 11 34.4% 10 30.3% 6-15 5 15.6% 0 0.0% 16-25 0 0.0% 0 0.0% 26-50 0 0.0% 0 0.0% + 50 0 0.0% 0 0.0% The Pearson chi-square test revealed no statistically significant difference between groups A and B in terms of flare grading after one week and four weeks post-operatively (p-value=0.23, p=0.067) ( Table 7 ). Table 7. Flare grading after one week and four weeks post-operatively. Study Groups P-value Group A Group B Grade No. % No. % Flare Grading after 1-week post-op None 28 84.8% 31 93.9% 0.23 Faint 5 15.2% 2 6.1% Mild 0 0.0% 0 0.0% Moderate 0 0.0% 0 0.0% Severe 0 0.0% 0 0.0% Flare Grading after 4 weeks post-op None 28 90.3% 33 100.0% 0.067 Faint 3 9.7% 0 0.0% Mild 0 0.0% 0 0.0% Moderate 0 0.0% 0 0.0% Severe 0 0.0% 0 0.0% The Pearson chi-square test revealed no statistically significant difference between groups A and B in terms of Grading of conjunctival congestion after one week and four weeks post-operatively (p-value=0.091, p=0.165), as seen in Table 8 . Table 8. Grading of conjunctival congestion after one week and four weeks post-operatively. Study Groups P-value Group A Group B Intensity No. % No. % Grading of conjunctival congestion 1-week post-op None 11 33.3% 20 60.6% 0.091 Trace 5 15.2% 2 6.1% Mild 7 21.2% 7 21.2% Moderate 0 0.0% 0 0.0% Severe 10 30.3% 4 12.1% Grading of conjunctival congestion 4 weeks post-op None 28 90.3% 31 93.9% 0.165 Trace 0 0.0% 0 0.0% Mild 0 0.0% 2 6.1% Moderate 1 3.2% 0 0.0% Severe 2 6.5% 0 0.0% There was no statistically significant difference between group A and group B regarding pain scores one and four weeks post-operatively (p-value=0.354, p=0.197), as determined by the Pearson chi-square test. However, group B had a greater proportion of patients who reported no pain during the initial week (69.7%) and again by the fourth week following the operation (93.9%) ( Table 9 ). Table 9. Pain scores one and four weeks post-operatively. Study Groups P-value Group A Group B Intensity No. % No. % Pain Score after 1-week post-op No pain 22 66.7% 23 69.7% 0.354 Mild 9 27.3% 10 30.3% Moderate 2 6.1% 0 0.0% Severe 0 0.0% 0 0.0% Pain Score after 4 weeks post-op No pain 26 83.9% 31 93.9% 0.197 Mild 5 16.1% 2 6.1% Moderate 0 0.0% 0 0.0% Severe 0 0.0% 0 0.0% Discussion Loteprednol etabonate 0.5% has been proven to be efficacious, well-tolerated, and safe in clinical trials for treating postoperative inflammation and pain after cataract surgery. 56 – 58 Research has shown that using loteprednol etabonate 0.5% suspension effectively decreases the presence of anterior chamber cells and flare reactions in patients undergoing cataract surgery leading to better clinical results and decreased inflammation. 59 Moreover, loteprednol etabonate has demonstrated effectiveness in treating inflammation associated with different eye conditions, such as cataract surgery. 60 Also dexamethasone 0.1% has been assessed for its efficacy in reducing inflammation following cataract surgery. Studies have demonstrated that sustained-release dexamethasone is advantageous for treating ocular pain and inflammation following cataract surgery. Nevertheless, in a direct comparison, loteprednol etabonate 0.5% has demonstrated equivalent effectiveness to prednisolone acetate 1.0% in managing postoperative inflammation in patients undergoing routine cataract surgery. 61 Randomized controlled studies have shown that loteprednol etabonate ophthalmic suspension 0.5% is clinically effective and safe for treating postoperative inflammation in patients who have undergone cataract surgery. These studies have found that very few patients, if any, experience a significant increase (≥10 mmHg) in intraocular pressure (IOP). In addition, studies have uncovered that loteprednol etabonate has a minimal impact on intraocular pressure (IOP) when used for a long period of time or in steroid-sensitive people. Furthermore, loteprednol etabonate has a significantly lower likelihood of increasing IOP than prednisolone acetate or dexamethasone. 62 Also, Thanathanee O. et al. reported that both loteprednol and dexamethasone were effective in post-photorefractive keratectomy (PRK) treatment. The dexamethasone group had a higher IOP increase of ≥ 5 mmHg than the loteprednol group (3/16 patients in the dexamethasone group vs. 1/16 patients in the loteprednol group). In our investigation, the dexamethasone group showed a mild increase in IOP after 4 weeks postoperatively compared to preoperatively but was clinically nonsignificant. 63 Our findings align with these aforementioned results, as we noticed no statistically significant difference in IOP between loteprednol etabonate and dexamethasone one week and four weeks following operation. However, dexamethasone showed a higher, although not statistically significant IOP increase in week 4. In contrast, Bilgin et al. (2019) found that loteprednol etabonate had no effect on IOP while dexamethasone increased IOP significantly, 26 and this difference in comparison to our study could be attributed to the fact that the Bilgin study was conducted for post-vitrectomy patients rather than post-cataract patients, those with more frequent dexamethasone usage. Regarding anterior chamber cells and pain score, a previous meta-analysis study showed that a significantly greater percentage of patients who received the dexamethasone intracanalicular insert, compared to those who received the placebo insert, experienced no pain on day 8 (7 days after the operation) in three important phases III trials. Additionally, the desired outcome of reduced inflammation (absence of anterior chamber cells) on day 14 (13 days after the operation) was achieved in two out of three trials. 64 In line with our findings, group B (the dexamethasone group) exhibited a higher percentage of patients who experienced no pain during the first week and the fourth week after the surgery. Also, our findings indicate that the dexamethasone group (group B) improved anterior chamber cells more than the group receiving Loteprednol etabonate 0.5% four weeks after the surgery. In summary, the dexamethasone intracanalicular insert proved effective and generally well tolerated in treating post-surgical ocular pain and inflammation after cataract surgery. Another study demonstrated that the intent-to-treat population consisted of 406 patients, with 203 patients assigned to each treatment group. By day 8, 30.5% of patients in the loteprednol etabonate group and 16.3% of patients in the vehicle group experienced complete resolution of ACC. Additionally, 72.9% and 41.9% of patients in the respective groups reported grade 0 pains. These differences were statistically significant (P<.001) for both comparisons. Statistically significant differences in the effectiveness of treating ACC and grade 0 pain were observed in favour of loteprednol etabonate on day 15 and day 18. 65 Our results differ slightly from the previous findings. We observed that the group treated with loteprednol etabonate did not achieve complete resolution of ACC and did not report grade 0 pain. These disparities could arise from variations in sample size, sociodemographic characteristics, and risk factors. Another research study demonstrated both groups exhibited decreased inflammation during the subsequent visits. No statistically significant distinction was observed between the LE/T and DM/T groups in terms of postoperative scores or measurements, such as discomfort, chemosis, secretion, conjunctival hyperemia, and conjunctival gap size (p>0.05), during the follow-up visits. No patients reported experiencing any allergic reactions to the medications. The intraocular pressures were within the normal range in both groups. 66 The results we obtained regarding flare grading and conjunctival congestion are comparable to the previous study, as no discernible distinction was observed between the two groups. Limitations of the study A larger study with a longer duration of follow-up might be advisable, particularly to evaluate long-term intraocular pressure changes and patient-reported outcomes regarding comfort and ease of use to consolidate that there is no difference between loteprednol and dexamethasone drops in changing or elevating IOP. Future studies are also urged to examine the long-term consequences of managing post-surgery inflammation with loteprednol etabonate and dexamethasone. However, etabonate 0.5% or dexamethasone 0.1% might need to be considered, based on the patient’s preference, since both medications successfully reduce post-operative inflammation. Additionally, it is advised to evaluate the patient’s medical history, probable side effects, and response to therapy while choosing between dexamethasone and loteprednol etabonate. In order to monitor the effectiveness of treatment following cataract surgery, it is recommended to periodically evaluate pressure (IOP), inflammation levels, anterior chamber (AC) response, flare, and discomfort during follow-up appointments. it is suggested to conduct research to study the long-term effects of using loteprednol etabonate and dexamethasone to manage post-surgery inflammation. Moreover, it is advised to conduct research on comparing the safety and long-term efficacy characteristics of dexamethasone and loteprednol etabonate for the treatment of inflammation following cataract surgery. Furthermore, it is encouraged to investigate the cost-effectiveness and patient satisfaction levels linked to both drugs in order to enhance treatment results for cataract patients. Conclusion Topical loteprednol etabonate 0.5% and topical dexamethasone 0.1% have comparable impacts on ocular indicators such as IOP, AC response, flare, conjunctival congestion, and pain following cataract surgery but dexamethasone tends to have a high spike of IOP ≥ 5mmHg in about 9.1% after four weeks of treatment. The comparison between loteprednol etabonate and dexamethasone in treating post-cataract surgery inflammation indicates that both medications are effective and well-tolerated. The choice amongst these corticosteroids may be based on the patient’s wishes and requirements Ethical approval The research project has been approved by the Institutional Review Board (IRB) of the University of Baghdad’s College of Medicine. The Declaration of Helsinki’s requirements and guidelines were scrupulously adhered to in the course of conducting the current research. On November 27, 2023, a local ethics authority (document permission number UoB.Med.21) verified the relevant documents and client data to verify the methodology of the study Author contributions L.B.T. conducted the investigation, wrote and refined the first draft of the document, participated in its design and provided financing and other forms of assistance, donated supplies, equipment, and lab animals, and finished the final copy of the research article. M.Q.Y.M.A.A. created the theoretical framework for the researched project, specified the parameters of the exploratory analysis, and outlined the main goals through.an in-depth assessment of the findings, supplemented with insightful criticism and supervision. Z.R.H. investigated and gathered material to supplement the printed paper, incorporated the methodological selection, and assisted with practicalities. Data availability statement 1. This is a prospective study enrolled patients diagnosed with cataract, 18 or older, who prepared and underwent cataract extraction surgery. All the patients after the surgery began the topical treatment and the patients were divided into two groups randomly 1:1 Group A received loteprednol etabonate drops 0.5%. Group B received dexamethasone drops 0.1%. Patients examined 1 week and 4 weeks after the surgery and recorded the following parameters • Intraocular pressure • Anterior chamber reaction • Anterior chamber flare • conjunctival congestion • pain Underlying data Zenodo: Raw Data, https://doi.org/10.5281/zenodo.14583348 This project contains the following underlying data: • excel row data.xlsx Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Extended data Zenodo: Extended Data, https://doi.org/10.5281/zenodo.14591793 This project contains the following underlying data: • extended data.pdf Data are available under the terms of the Creative Commons Attribution 4.0 International license (CC-BY 4.0). Acknowledgment The authors thank the College of Medicine at the University of Baghdad in offering support for the course of this experiment. References 1. Hassan OA, Abu-Raghif AR, Rasheed AM, et al. : Effect of Foeniculum vulgare seed aqueous extract eye drops on selenite induced cataract in rabbits. Int. J. Pharm. Sci. Res. 2017; 83–87. 2. Wang W, Yan W, Muller A, et al. : A Global View on Output and Outcomes of Cataract Surgery With National Indices of Socioeconomic Development. Invest. Ophthalmol. Vis. Sci. 2017 Jul 1; 58 (9): 3669–3676. PubMed Abstract | Publisher Full Text 3. Rahim YA, Hameed Ali MA, Abbas MF: Prevalence and Risk Factors for Eye Problems among 20-65 Years Old Iraqi Diabetics Patients. J. Fac. Med. Baghdad. 2008; 50 (2): 166–174. Publisher Full Text 4. Rasheed AM: Aiming For Emmetropia after Cataract Surgery. Iraqi Postgrad. Med. J. 2013; 12. 5. Al-Quriashi NK, Essa SO: 0.1 Second versus 0.2 Second pulse duration of Frequency Doubled Nd: YAGLaser in treatment of Clinically Significant Diabetic Maculopathy. J. Fac. Med. Baghdad. 2009; 51 (1): 112–115. Publisher Full Text 6. Abdul-Hasan AA, Yassin BAG: Health Literacy of Diabetic Patients and its Impact on Disease Outcome. J. Fac. Med. Baghdad. 2018; 60 (1): 65–68. Publisher Full Text 7. Hassan ZM, Hamdi RA, Al Bassam EN: Evaluation of the Role of Serum Malondialdehyde in the Pathogenesis of Diabetic Retinopathy. J. Fac. Med. Baghdad. 2022; 64 (3). Publisher Full Text 8. Swayeh N, Kadhim H: Effects of methanol extract of Corchorus olitorius cultivated in Iraq on high fat diet plus streptozotocin-induced type ii diabetes in rats. Int. J. Drug Deliv. Technol. 2022; 12 (2): 754–759. Publisher Full Text 9. Swayeh NH, Kadhim HM: Control of Glycemia and Dyslipidemia by Crude Methanolic Extracts of Iraqi Abelmoschus Esculentus and Corchorus Olitorius and Their Combination on Streptozocin-Induced Type 2 Diabetes Mellitus in Rats. Lab. Diagn. East. Eur. 2024; 13 (2): 21–33. 10. Aljawad FH, Hashim HM, Jasim GA, et al. : Effects of atorvastatin and coenzyme Q10 on glycemic control and lipid profile in type 2 diabetic patients. Int. J. Pharm. Sci. Rev. Res. 2015; 34 (2): 183–186. 11. Kadhim HM: Antiinflmmatory and antihyperlipidemic effect of adjuvant cinnamon in type 2 diabetic patients. Int. J. Pharm. Sci. Rev. Res. 2016; 41 : 88–98. 12. Raghif ARA, Yaseen YA, Dawood MH: Effects of Coenzyme Q10 Administration on Glucose Homeostasis Parameters in Prediabetic Patients. J. Pharm. Sci. Res. 2017; 9 (11): 2274–2277. 13. Abbas AH: Antihyperglycemic, antihyperlipidiemic effects of ethanol extracts of Nigella sativa and Apium graveolens and their combination in streptozocin/high fat diet induced hyperglycemic mice. World J. Pharm. Pharm. Sci. 2018; 7 : 85–117. 14. Abbas AH: Antihyperglycemic, Antihyperlipidemic Effects Of Ethanol Extract Of Nigella Sativa Seeds In Streptozocin/High Fat Diet Induced Hyperglycemic. World J. Pharm. Pharm. Sci 2018; 7 (3): 110–122. 15. Kessel L, Andresen J, Erngaard D, et al. : Indication for cataract surgery. Do we have evidence of who will benefit from surgery? A systematic review and meta-analysis. Acta Ophthalmol. 2016 Feb; 94 (1): 10–20. PubMed Abstract | Publisher Full Text | Free Full Text 16. Abood ZB, Kareem AA: Changes of Anterior Chamber Biometry and Relationship to Intraocular Pressure Changes after Phacoemulsification Surgery in Non-Glaucomatous Eyes. Iraqi Postgraduate Medical Journal. 2023; 22 (2): 192–196. Publisher Full Text 17. Liu YC, Wilkins M, Kim T, et al. : Cataracts. Lancet. 2017 Aug 5; 390 (10094): 600–612. PubMed Abstract | Publisher Full Text 18. Sharquie KE, Turki KM, Abu-Raghif AR, et al. : Oxidative stress in patients with premature hair grayness. Saudi Med. J. 2005; 26 (8): 1310–1311. PubMed Abstract 19. Dawood YF, Issa AF, Mohammed Ali SS: Changes in anterior chamber biometry and intraocular pressure after uneventful phacoemulsification in non-glaucomatous eyes. Med. Hypothesis Discov. Innov. Ophthalmol. 2023 Spring; 12 (1): 28–35. PubMed Abstract | Publisher Full Text | Free Full Text 20. Hameed FFM: Role of Cataract Surgery in IOP Lowering. Al-Qadisiyah Med. J. 2017; 13 (23): 125–129. Publisher Full Text 21. Hameed AH, Kadhim HM, Rasheed AM: The effects of topical adenosine agonists (Limonene) on induced ocular hypertension in rabbits. J. Glob. Pharma Technol. 2020; 12 (1): 579–588. 22. Asbell PA, Dualan I, Mindel J, et al. : Age-related cataract. Lancet. 2005 Feb 12-18; 365 (9459): 599–609. eng. PubMed Abstract | Publisher Full Text 23. Abdul-Sattar RS, Al-Maini AH: The Advantages of Combined Regional and General Anesthesia in Ophthalmic Surgery in Children. J. Fac. Med. Baghdad. 2023; 65 (3): 173–178. Publisher Full Text 24. Claesson M, Armitage WJ, Stenevi U: Corneal oedema after cataract surgery: predisposing factors and corneal graft outcome. Acta Ophthalmol. 2009 Mar; 87 (2): 154–159. PubMed Abstract | Publisher Full Text 25. Day AC, Wormald R, Coronini-Cronberg S, Smith R: The Royal College of Ophthalmologists’ Cataract Surgery Commissioning Guidance: executive summary. Eye (Lond.). 2016 Mar; 30 (3): 498–502. PubMed Abstract | Publisher Full Text | Free Full Text 26. Bilgin AB, Dogan ME, Ayaz Y, et al. : Comparison of Efficacy and Safety of Loteprednol Etabonate 0.5% and Topical Dexamethasone 1% in Post-Vitrectomy Inflammation. Ocul. Immunol. Inflamm. 2019; 27 (2): 312–318. PubMed Abstract | Publisher Full Text 27. Holland EJ, Bartlett JD, Paterno MR, et al. : Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea. 2008; 27 (1): 50–55. PubMed Abstract | Publisher Full Text 28. Fung AT, Tran T, Lim LL, et al. : Local delivery of corticosteroids in clinical ophthalmology: A review. Clin. Experiment. Ophthalmol. 2020 Apr; 48 (3): 366–401. PubMed Abstract | Publisher Full Text | Free Full Text 29. Edelman JL: Differentiating intraocular glucocorticoids. Ophthalmologica. 2010; 224 (Suppl. 1): 25–30. Publisher Full Text 30. Gaballa SA, Kompella UB, Elgarhy O, et al. : Corticosteroids in ophthalmology: drug delivery innovations, pharmacology, clinical applications, and future perspectives. Drug Deliv. Transl. Res. 2021 2021/06/01; 11 (3): 866–893. PubMed Abstract | Publisher Full Text 31. Ridha-Salman H, Shihab EM, Hasan HK, et al. : Mitigative Effects of Topical Norfloxacin on an Imiquimod-Induced Murine Model of Psoriasis. ACS Pharmacol. Transl. Sci. 2024 2024/08/02; 7 (9): 2739–2754. Publisher Full Text 32. Sulaiman RS, Kadmiel M, Cidlowski JA: Glucocorticoid receptor signaling in the eye. Steroids. 2018; 133 : 60–66. PubMed Abstract | Publisher Full Text | Free Full Text 33. Ridha-Salman H, Al-Zubaidy AA, Abbas AH, et al. : The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation. Naunyn Schmiedeberg’s Arch. Pharmacol. 2024 2024/09/10; 398 : 1–21. Publisher Full Text 34. Abbas AH, Abbas ZH, Ridha-Salman H, et al. : The attenuated effects of Topical Empagliflozin on Imiquimod-induced Model of Psoriasis in Mice. J. Trop. Life Sci. 2024; 14 (3): 459–468. Publisher Full Text 35. Abbas A, Abd A, Salman H, et al. : The Attenuated Effects of Cimifugin on Imiquimod-Induced Model of Psoriasis in Mice. Lat. Am. J. Pharm. 2023 2022/06/22; 42 (special issue): 362–369. 36. Oubaid EN, Abu-Raghif A, Al-Sudani IM: Ibudilast ameliorates experimentally induced colitis in rats via down-regulation of proinflammatory cytokines and myeloperoxidase enzyme activity. Pharmacia. 2023; 70 (1): 187–195. Publisher Full Text 37. Khafaji AWM, Al-Zubaidy AAK, Farhood IG, et al. : Ameliorative effects of topical ramelteon on imiquimod-induced psoriasiform inflammation in mice. Naunyn Schmiedeberg’s Arch. Pharmacol. 2024 2024/03/06; 397 (8): 6231–6248. PubMed Abstract | Publisher Full Text 38. Khorsheed SM, Abu-Raghif A, Ridha-Salman H: Alleviative Effects of Combined Topical Melatonin and Rutin on Imiquimod-Induced Psoriasis Mouse Model. Pharmacia. 2024; 71 : 1–13. Publisher Full Text 39. Alhashem G, Raghif AR, Abbas AA: The Effect of Liraglutide on Biochemical Markers of Bone Turnover in Rats Treated by Dexamethasone. Int. J. Drug Deliv. Technol. 2022; 12 : 598–602. 40. Kadhim H, Gatea F, Raghif AA, et al. : Role of Topical Ritodrine Hydrochloride in Experimentally Induced Hypertrophic Scar in Rabbits. Iraqi J. Pharm. Sci. 2022; 31 (2): 260–270. (P-ISSN 1683-3597 E-ISSN 2521-3512). 41. Ghazy DN, Abu-Raghif AR: Effects of Apremilast on Induced Hypertrophic Scar of Rabbits. Arch. Razi. Inst. 2021 Dec; 76 (6): 1803–1813. PubMed Abstract | Free Full Text 42. Khorsheed SM, Raghif ARA: Anti-proliferative, Anti-oxidant and Anti-inflammatory Effects of Topical Rutin on Imiquimod-Induced Psoriasis in Mice. Pak. J. Life Soc. Sc. 2024; 22 (1): 1962–1976. 43. Salman HR, Alzubaidy AA, Abbas AH, et al. : Attenuated effects of topical vinpocetine in an imiquimod-induced mouse model of psoriasis. J. Taibah Univ. Med. Sci. 2024 2024/02/01/; 19 (1): 35–53. PubMed Abstract | Publisher Full Text | Free Full Text 44. Kato M, Hagiwara Y, Oda T, et al. : Beneficial pharmacological effects of selective glucocorticoid receptor agonist in external eye diseases. J. Ocul. Pharmacol. Ther. 2011; 27 (4): 353–360. PubMed Abstract | Publisher Full Text 45. Abed-Mansoor A, Abu-Raghif AR: Attenuated effects of rivastigmine in induced cytokine storm in mice. J. Emerg. Med. Trauma Acute Care. 2022; 2022 (3): 12. Publisher Full Text 46. Manna MJ, Abu-raghif A, Muhsin HY: The effect of Niclosamide in acetic acid induce colitis: an experimental study. Prensa méd argent. 2019; pp. 309–316. 47. Lebrize S, Arnould L, Bourredjem A, et al. : Intraocular pressure changes after intravitreal fluocinolone acetonide implant: results from four European countries. Ophthalmol. Therapy. 2022; 11 (3): 1217–1229. PubMed Abstract | Publisher Full Text | Free Full Text 48. Hussein MQ, Kadim HM, Abdulsahib WK: Effect of telmisartan on intra-ocular pressure in induced open angle glaucoma in rabbits. Int. J. Sci. Res. ISSN. 2017; 6 (10): 1565–1661. 49. Alfaris R, Al-Kinani KK: Preparation and Characterization of Prednisolone Acetate Microemulsion for Ophthalmic Use. J. Fac. Med. Baghdad. 2023; 65 (3): 205–211. Publisher Full Text 50. Whalen K, Feild C, Radhakrishnan R: Lippincott illustrated reviews: pharmacology. Seventh edition.Philadelphia: Wolters Kluwer Philadelphia; 2019. 51. Rang HP, Dale MM: Rang & Dale’s pharmacology. 6th ed.[Edinburgh]: Churchill Livingstone; Elsevier [Edinburgh]; 2007. 52. Salman HR, Al-Zubaidy AA, Abbas AH, et al. : The ameliorative effects of topical gemifloxacin alone or in combination with clobetasol propionate on imiquimod-induced model of psoriasis in mice. Naunyn Schmiedeberg’s Arch. Pharmacol. 2024 2024/01/01; 397 (1): 599–616. PubMed Abstract | Publisher Full Text 53. Pavesio CE, DeCory HH: Treatment of ocular inflammatory conditions with loteprednol etabonate. Br. J. Ophthalmol. 2008; 92 (4): 455–459. PubMed Abstract | Publisher Full Text 54. Trusko B, Thorne J, Jabs D, et al. : The Standardization of Uveitis Nomenclature (SUN) project: development of a clinical evidence base utilizing informatics tools and techniques. Methods Inf. Med. 2013; 52 (3): 259. 55. Ehrenberg M, Zolotariov E, Loeb E, et al. : Combining sodium hyaluronate and polyvinylpyrrolidone therapies for the rabbit cornea: a new approach to relief of the human dry eye syndrome. Curr. Eye Res. 2015; 40 (9): 913–922. PubMed Abstract | Publisher Full Text 56. Lyseng-Williamson KA: Loteprednol Etabonate Ophthalmic Gel 0.5 %: A Review of Its Use in Post-Operative Inflammation and Pain Following Ocular Surgery. Drugs. 2013; 73 (9): 949–958. PubMed Abstract | Publisher Full Text 57. Fong R, Leitritz MA, Siou-Mermet R, et al. : Loteprednol Etabonate Gel 0.5% for Postoperative Pain and Inflammation After Cataract Surgery: Results of a Multicenter Trial. Clin. Ophthalmol. 2012; 6 : 1113–1124. PubMed Abstract | Publisher Full Text | Free Full Text 58. Memon ZA, Zafar O, Farooq A, et al. : Cataract Surgery. Professional Med. J. 2017; 24 (12): 1812–1817. Publisher Full Text 59. Lee H, Chung B, Kim KS, et al. : Effects of Topical Loteprednol Etabonate on Tear Cytokines and Clinical Outcomes in Moderate and Severe Meibomian Gland Dysfunction: Randomized Clinical Trial. Am. J. Ophthalmol. 2014; 158 (6): 1172–83.e1. PubMed Abstract | Publisher Full Text 60. Pirouzian A, Craven ER: Critical Appraisal of Loteprednol Ointment, Gel, and Suspension in the Treatment of Postoperative Inflammation and Pain Following Ocular and Corneal Transplant Surgery. Clin. Ophthalmol. 2014; 8 : 379–387. PubMed Abstract | Publisher Full Text | Free Full Text 61. Walters TR, Bafna S, Vold SD, et al. : Efficacy and Safety of Sustained Release Dexamethasone for the Treatment of Ocular Pain and Inflammation After Cataract Surgery: Results From Two Phase 3 Studies. J. Clin. Exp. Ophthalmol. 2016; 07 (04). Publisher Full Text 62. Amon M, Busin M: Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use. Int. Ophthalmol. 2012 Oct; 32 (5): 507–517. PubMed Abstract | Publisher Full Text | Free Full Text 63. Thanathanee O, Sriphon P, Anutarapongpan O, et al. : A randomized controlled trial comparing dexamethasone with loteprednol etabonate on postoperative photorefractive keratectomy. J. Ocul. Pharmacol. Ther. 2015 Apr; 31 (3): 165–168. PubMed Abstract | Publisher Full Text 64. Lee A, Blair HA: Dexamethasone intracanalicular insert: a review in treating post-surgical ocular pain and inflammation. Drugs. 2020; 80 (11): 1101–1108. PubMed Abstract | Publisher Full Text | Free Full Text 65. Rajpal RK, Roel L, Siou-Mermet R, et al. : Efficacy and safety of loteprednol etabonate 0.5% gel in the treatment of ocular inflammation and pain after cataract surgery. J. Cataract Refract. Surg. 2013; 39 (2): 158–167. PubMed Abstract | Publisher Full Text 66. Salman İA: Comparison of the safety and efficacy of loteprednol etabonate 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% following strabismus surgery. The Eurasian. J. Med. 2016; 48 (3): 186. Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 20 Jan 2025 ADD YOUR COMMENT Comment Author details Author details 1 Msc candidate (Pharmacology), Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, +964, Iraq 2 PhD (Pharmacology), Department of Pharmacology, College of Medicine, University of Baghdad, Baghdad, Baghdad Governorate, Iraq 3 Republic of Iraq Ministry of Health, Ibn Al Haitham Teaching Eye Hospital, Baghdad, Iraq Leqaa Basil Taha Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software Mohammed Qasim Yahya Malallah A. Al-Atrakji Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization zaid Rajab Hussein Roles: Conceptualization, Investigation, Software, Supervision, Validation, Visualization Competing interests No competing interests were disclosed. Grant information The author(s) declared that no grants were involved in supporting this work. Article Versions (1) version 1 Published: 20 Jan 2025, 14:114 https://doi.org/10.12688/f1000research.158920.1 Copyright © 2025 Taha LB et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads F1000Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Taha LB, Al-Atrakji MQYMA and Hussein zR. A comparative study of the effects of topical dexamethasone 0.1% and loteprednol etabonate 0.5% on clinical ocular parameters in Iraqi patients following cataract surgery [version 1; peer review: awaiting peer review] . F1000Research 2025, 14 :114 ( https://doi.org/10.12688/f1000research.158920.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: AWAITING PEER REVIEW AWAITING PEER REVIEW ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Comments on this article Comments (0) Version 1 VERSION 1 PUBLISHED 20 Jan 2025 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status AWAITING PEER REVIEW Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert Browse by related subjects Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with F1000Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "A comparative study of the effects of topical...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/14-114/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/14-114/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/14-114/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Taha LB et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://f1000research.com/articles/14-114/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://f1000research.com/articles/14-114", templates : { twitter : "A comparative study of the effects of topical dexamethasone 0.1%.... Taha LB et al., published by " + "@F1000Research" + ", https://f1000research.com/articles/14-114/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/158920/174576") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "174576"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "361605": 0, "361604": 0, "361607": 0, "361606": 0, "361601": 0, "366209": 0, "366208": 0, "361603": 0, "366211": 0, "361602": 0, "366210": 0, "361609": 0, "361608": 0, "361610": 0, "368165": 0, "368181": 0, "368180": 0, "368183": 0, "368182": 0, "368176": 0, "368179": 0, "368178": 0, "363327": 0, "363326": 0, "368185": 0, "368184": 0, "363333": 0, "363332": 0, "363335": 0, "363334": 0, "363329": 0, "363328": 0, "363331": 0, "363330": 0, "392149": 0, "392148": 0, "392151": 0, "392150": 0, "392147": 0, "392146": 0, "392153": 0, "392152": 0, "392155": 0, "392154": 0, "366205": 0, "366204": 0, "366207": 0, "366206": 0, "366203": 0, "366202": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "33ae6709-cd72-43ae-9708-18a90c2fe872"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing. Browse Gateways Collections How it Works Contact For Developers Cookie Notice Privacy Notice RSS Submit Your Research Follow us © 2012-2026 F1000 Research Ltd. ISSN 2046-1402 | Legal | Partner of Research4Life • CrossRef • ORCID • FAIRSharing R.templateTests.simpleTemplate = R.template(' $text $text $text $text $text '); R.templateTests.runTests(); var F1000platform = new F1000.Platform({ name: "f1000research", displayName: "F1000Research", hostName: "f1000research.com", id: "1", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');}); // $(function(){R.ui.dropdowns('.dropdown-for-referees');}); $(document).ready(function () { if ($(".cookie-warning").is(":visible")) { $(".sticky").css("margin-bottom", "35px"); $(".devices").addClass("devices-and-cookie-warning"); } $(".cookie-warning .close-button").click(function (e) { $(".devices").removeClass("devices-and-cookie-warning"); $(".sticky").css("margin-bottom", "0"); }); $("#tweeter-feed .tweet-message").each(function (i, message) { var self = $(message); self.html(linkify(self.html())); }); $(".partner").on("mouseenter mouseleave", function() { $(this).find(".gray-scale, .colour").toggleClass("is-hidden"); }); }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });